Get started
Author

David A. Sorrell

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
2017 · Ursula A. Germann, Brinley F. Furey, et al. · Molecular Cancer Therapeutics · 240
Plant cyclins: a unified nomenclature for plant A-, B- and D-type cyclins based on sequence organization
1996 · Jean-Pierre Renaudin, John H. Doonan, et al. · Plant Molecular Biology · 239
The interface between the cell cycle and plant growth regulators: a mini review
2001 · Dennis Francis, David A. Sorrell · Plant Growth Regulation · 158
Cell Cycle Regulation of Cyclin-Dependent Kinases in Tobacco Cultivar Bright Yellow-2 Cells
2001 · David A. Sorrell, Margit Menges, et al. · PLANT PHYSIOLOGY · 134
PDF
Distinct Cyclin D Genes Show Mitotic Accumulation or Constant Levels of Transcripts in Tobacco Bright Yellow-2 Cells1
1999 · David A. Sorrell, Bruno Combettes, et al. · PLANT PHYSIOLOGY · 132
PDF
A WEE1 homologue from Arabidopsis thaliana
2002 · David Sorrell, Angela Marchbank, et al. · Planta · 113
Targeted modification of mammalian genomes
2005 · David A. Sorrell, Andreas F. Kolb · Biotechnology Advances · 101
Type IX Collagen Interacts with Fibronectin Providing an Important Molecular Bridge in Articular Cartilage
2011 · Philippa Parsons, Sophie J. Gilbert, et al. · Journal of Biological Chemistry · 52
Synthesis and biological profiling of tellimagrandin I and analogues reveals that the medium ring can significantly modulate biological activity
2012 · Shaojun Zheng, Luca Laraia, et al. · Organic & Biomolecular Chemistry · 46
Tobacco BY‐2 cells expressing fission yeast cdc25 bypass a G2/M block on the cell cycle
2005 · Craig B. Orchard, Ilario Siciliano, et al. · The Plant Journal · 44
PDF
The Arabidopsis CDC25 induces a short cell length when overexpressed in fission yeast: evidence for cell cycle function
2004 · D. A. Sorrell, D. Chrimes, et al. · New Phytologist · 33
PDF
The Arabidopsis 14-3-3 protein, GF14?, binds to the Schizosaccharomyces pombe Cdc25 phosphatase and rescues checkpoint defects in the rad24? mutant
2003 · David A. Sorrell, Angela M. Marchbank, et al. · Planta · 31
Abstract 4693: The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance
2015 · Ursula Germann, Brinley Furey, et al. · Cancer Research · 22
Recombinase mediated cassette exchange into genomic targets using an adenovirus vector
2010 · David A. Sorrell, Claire J. Robinson, et al. · Nucleic Acids Research · 21
PDF
Regulation of genes encoding proteolytic enzymes during mammary gland development
2005 · David A Sorrell, Malgorzata Szymanowska, et al. · Journal of Dairy Research · 20
Mammary gland development is delayed in mice deficient for aminopeptidase N
2012 · Andreas F. Kolb, David Sorrell, et al. · Transgenic Research · 11
PDF
A Novel Cell-Based, High-Content Assay for Phosphorylation of Lats2 by Aurora A
2011 · Amy Emery, David A. Sorrell, et al. · SLAS DISCOVERY · 11
PDF
A Flexible, Pooled CRISPR Library for Drug Development Screens
2020 · Maximilian Blanck, Milka B. Budnik-Zawilska, et al. · The CRISPR Journal · 7
PDF
Abstract 5160: Development of REDX05358, a novel highly selective and potent pan RAF inhibitor and a potential therapeutic for BRAF and RAS mutant tumors
2017 · Helen Mason, Simon Scrace, et al. · Cancer Research · 4
Abstract 1057: Significant efficacy demonstrated with the combination of ulixertinib (ERK1/2 inhibitor) and CDK4/6 inhibitors in MAPK altered models
2022 · Caroline M. Emery, Brian Corgiat, et al. · Cancer Research · 2
Recombinase-Mediated Cassette Exchange Using Adenoviral Vectors
2017 · Andreas F. Kolb, Christopher Knowles, et al. · Methods in molecular biology · 2
Plant D-type (CycD) cyclins and the regulation of the plant cell cycle
1999 · D. A. Sorrell, C. Riou-Khamlichi, et al. · Current plant science and biotechnology in agriculture · 2
Supplementary Data: Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (ulixertinib) from Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
2023 · Ursula A. Germann, Brinley F. Furey, et al.
Figure S4 from Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
2023 · Ursula A. Germann, Brinley F. Furey, et al.
Figure S5 from Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
2023 · Ursula A. Germann, Brinley F. Furey, et al.
Works count: 42
Citation count: 1,425
H-index: 15
I10-index: 17
Year
Topic
Type